Srinivas Nalamachu
Overview
Explore the profile of Srinivas Nalamachu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grigsby E, Radnovich R, Nalamachu S
Local Reg Anesth
. 2021 Sep;
14:125-132.
PMID: 34557036
Purpose: Treatment of chronic pain associated with occipital neuralgia (ON) is complex, and no consensus statement or guidelines have been published for ON management. This pilot study evaluated the efficacy...
2.
Tack J, Camilleri M, Hale M, Morlion B, Nalamachu S, Webster L, et al.
Clin Gastroenterol Hepatol
. 2021 May;
20(4):855-863.
PMID: 33965574
Background & Aims: Opioids have a role in chronic pain management. However, opioid-induced constipation may cause patients to skip or reduce opioid doses, leading to inadequate pain relief and negatively...
3.
Nalamachu S, Pergolizzi J, Kaye R
J Pain Res
. 2020 Dec;
13:3059-3069.
PMID: 33262641
Objective: Use of skeletal muscle relaxants (SMRs) for acute muscle spasm is confounded by central nervous system adverse events (AEs), including somnolence. Tolperisone is an SMR that does not appear...
4.
Nalamachu S, Gudin J
J Pain Res
. 2020 Oct;
13:2343-2354.
PMID: 33061549
Topical and transdermal formulations are a common means of pharmaceutical drug delivery. If a drug is able to penetrate transcutaneously, the skin is an ideal site for the delivery of...
5.
Nalamasu R, Nalamachu S
Phys Med Rehabil Clin N Am
. 2020 Apr;
31(2):205-217.
PMID: 32279724
The Chronic pain epidemic is a pressing public health crises facing the United States. Currently, more than 100 million Americans suffer from chronic pain, with chronic pain being among the...
6.
Nalamachu S, Gudin J, Datto C, Coyne K, Poon J, Hu Y
J Opioid Manag
. 2018 Jul;
14(3):211-221.
PMID: 30044486
Objective: Efficacy and safety of naloxegol, a peripherally acting µ-opioid receptor antagonist that significantly reduces opioid-induced constipation (OIC), were assessed for patient subgroups defined post hoc by baseline maintenance opioid...
7.
Rauck R, Oh D, Singla N, Koch C, Parikh N, Nalamachu S, et al.
Clin Drug Investig
. 2018 Jun;
38(8):715-726.
PMID: 29909433
Background And Objectives: Fentanyl sublingual spray may be a viable alternative to intravenous (IV) opioids for the treatment of acute pain. As patients with acute pain may include those who...
8.
Webster L, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, et al.
Pain
. 2018 Feb;
159(5):987-994.
PMID: 29419653
The long-term safety of naldemedine, a peripherally acting µ-opioid receptor antagonist, was evaluated in patients with opioid-induced constipation and chronic noncancer pain in a 52-week, randomized, double-blind, phase 3 study....
9.
Rauck R, Oh D, Singla N, Koch C, Parikh N, Nalamachu S, et al.
Curr Med Res Opin
. 2017 Sep;
33(11):1921-1933.
PMID: 28942715
Objective: Fentanyl sublingual spray, with its rapid onset for pain relief, may be efficacious in the management of acute or post-operative pain. Because patients in these settings may be opioid-naïve,...
10.
Rauck R, Oh D, Parikh N, Koch C, Singla N, Yu J, et al.
Curr Med Res Opin
. 2017 Jul;
33(11):1915-1920.
PMID: 28681626
Objective: Fentanyl sublingual spray offers rapid pain relief in opioid-tolerant cancer patients, and may be useful in acute or post-operative pain. Both opioid-naïve and non-tolerant patients are likely to receive...